Related Experiment Video
Updated: Jun 24, 2026
12:44
A General Method for Evaluating Incubation of Sucrose Craving in Rats
Published on: November 4, 2011
Inhibitory Effect of Codeine on Sucrase Activity
Dariush Minai-Tehrani1, Saeed Minoui2, Marzie Sepehre1
1BioResearch Lab, Faculty of Biological Sciences, Shahid Beheshti University, G.C, Tehran, Iran
Drug Metabolism Letters
|April 10, 2009
Summary
Codeine non-competitively inhibits yeast sucrase, decreasing Vmax but not Km. This study quantines codeine
Area of Science:
- Biochemistry
- Enzymology
- Pharmacology
Background:
- Codeine is a widely used analgesic.
- Yeast sucrase is a key enzyme in carbohydrate metabolism.
- Understanding enzyme inhibition is crucial for drug development.
Purpose of the Study:
- To investigate the inhibitory effect of codeine on yeast sucrase activity.
- To determine the type of inhibition and kinetic parameters.
Main Methods:
- Enzyme kinetics assays were performed.
- Double reciprocal plots (Lineweaver-Burk) were used to determine inhibition type.
- Dixon plots were utilized to calculate the inhibition constant (Ki).
Main Results:
- Codeine exhibited non-competitive inhibition of yeast sucrase.
- The Michaelis constant (Km) remained unchanged (approx. 11.5 mM).
- The maximum velocity (Vmax) decreased in the presence of codeine (approx. 8.8 mM/min).
- The inhibition constant (Ki) was determined to be 0.42 mM.
- The IC50 value was found to be 0.875 mM.
Conclusions:
- Codeine acts as a non-competitive inhibitor of yeast sucrase.
- The findings provide insights into the mechanism of codeine's interaction with enzymes.
- This research contributes to understanding the biochemical effects of codeine.
More Related Videos
10:24NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases
Published on: June 30, 2019
14:57Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases
Published on: October 10, 2020
Related Concept Videos
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:19Depolarizing Blockers: Pharmocokinetics
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
01:30Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...